Response to brentuximab vedotin by CD30 expression: Results from five trials in PTCL, CTCL, and B-cell lymphomas.

Deepa Jagadeesh,Steven M. Horwitz,Nancy L. Bartlett,Ranjana H. Advani,Eric D. Jacobsen,Madeleine Duvic,Ashish Gautam,Shangbang Rao,Matthew D. Onsum,M. Fanale,Youn H. Kim

Response to brentuximab vedotin by CD30 expression: Results from five trials in PTCL, CTCL, and B-cell lymphomas.

2019

Deepa Jagadeesh
Steven M. Horwitz
Nancy L. Bartlett
Ranjana H. Advani
Eric D. Jacobsen
Madeleine Duvic
Ashish Gautam
Shangbang Rao
Matthew D. Onsum
M. Fanale
Youn H. Kim

7543Background: Brentuximab vedotin (BV), an antibody-drug conjugate targeting CD30, has been evaluated in multiple trials in patients (pts) with peripheral T-cell lymphoma (PTCL), cutaneous T-cell...

Keywords:

Pathology
Lymphoma
Oncology
Conjugate
Brentuximab vedotin
Internal medicine
CD30
B cell
Medicine
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations